Navigation Links
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Date:11/1/2007

to fund operations for the next two to three years.

Pipeline Update

GATTEX

Nycomed has confirmed to NPS its commitment to license GATTEX for development and commercialization outside of North America. Under the terms of the agreement announced in September 2007, Nycomed will now pay NPS the $25 million balance of the $35 million up-front payment due NPS for the rights to develop and market GATTEX outside North America. In October 2007, NPS announced top-line results of the Phase 3 study of GATTEX in patients with short bowel syndrome (SBS). The company has requested a meeting to discuss the next steps in the drug's regulatory approval process with the FDA this year. NPS believes GATTEX could generate U.S. sales of between $150 and $250 million in this indication.

NPS is also running pre-clinical studies of GATTEX in support of a pediatric IND in necrotizing enterocolitis. NEC affects 12,000 neonates annually in the U.S. and mortality approaches 50% in infants weighing less than fifteen-hundred grams. Additional preclinical studies in chemotherapy-induced gastrointestinal mucositis will be initiated very soon. Chemotherapy-induced GI mucositis affects over 500,000 cancer patients in the U.S. annually.

Cinacalcet

NPS recently announced that Kirin Pharma has received approval to market cinacalcet HCl in Japan. This regulatory event triggered a $2 million milestone payment to NPS.

PREOS

In September 2007, the FDA granted orphan drug status for PREOS as a treatment for hypoparathyroidism. The company is currently supporting a two-year study with PREOS in patients with hypoparathyroidism. The study was initiated by Dr. John Bilezikian at Columbia University and is now 96% enrolled.

The company believes that as a result of recent fundraising activities, sales of non-core assets and the GATTEX partnership with Nycomed, it now has the financial resources to fund the continued U.S. development of PREOS in a variety of ind
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Terracon Corporation has announced the introduction of a ... This addition to the company’s industry-leading line of custom ... available in 125 or 250 gallon capacities. It ... or less. , The new pre-engineered TerraPure tank offers ... TerraPure tank line – plus quick turnaround. An ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... develops and commercializes proprietary technologies and products for advanced ... been approved for trading in the United ... is expected to commence on September 17, 2014 on ... continue to trade on the TSX Venture Exchange under ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Beckman ... advances science and healthcare, has renewed its agreement with ... As part of the agreement, Personify will continue to ... sustained emphasis on recruitment analytics, including time-to-fill, time-to-source and ... renew our agreement with Personify was based on the ...
(Date:9/17/2014)... The Pistoia Alliance, a global not ... to innovation in life sciences R&D through pre-competitive ... as Executive Director Business Development North America, as ... , Carmen joins the Pistoia Alliance from Accelrys ... Accelrys, she managed various life sciences and material ...
Breaking Biology Technology:Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... Up in the sky. It's a bird. It's a plane. It's ... denial in a single bound. Indeed, lately the media has been ... to result from the mass exodus of Baby Boomers from the ... believe that this trend and its impacts on businesses are black ...
... Milwaukee, Wis. - The National Cancer Institute ... Medical College of Wisconsin to study the growth ... second successful renewal of the grant that was first awarded ... ongoing principal investigator. , ,She and other investigators are developing ...
... This is the ninth in a series of articles ... sectors. The most recent article focused on worker classification. ... The idea is developed. Lawyers and accountants are on ... is formed. The name has been chosen. Perhaps workers, ...
Cached Biology Technology:Shades of gray: Business impacts of an aging workforce 2Shades of gray: Business impacts of an aging workforce 3Shades of gray: Business impacts of an aging workforce 4Shades of gray: Business impacts of an aging workforce 5Shades of gray: Business impacts of an aging workforce 6Early Stage, Step 9: Raising capital in the securities landscape 2Early Stage, Step 9: Raising capital in the securities landscape 3Early Stage, Step 9: Raising capital in the securities landscape 4
(Date:9/17/2014)... of Spanish researchers have obtained the first partial genome ... century pig found at the site of the Montsoriu ... ancient pig is closely related to today,s Iberian pig. ... crossed with modern Iberian pigs. , The study, published ... aspects of pig species, and particularly on that of ...
(Date:9/17/2014)... in the human retinoblastoma protein gene are a leading ... have turned to fruit fly eyes to unlock the ... a paper featured on the cover of the current ... Michigan State University researchers provide the first detailed examination ... in the human cancer gene, said Irina Pushel, MSU ...
(Date:9/17/2014)... Washington, DC A team of researchers working on a ... that coral growth rates have plummeted 40% since the ... playing an important role in this perilous slowdown. ... peril facing coral reefs, the team compared current measurements ... Great Barrier Reef with similar measurements taken more than ...
Breaking Biology News(10 mins):Iberian pig genome remains unchanged after 5 centuries 2Abnormal properties of cancer protein revealed in fly eyes 2Coral growth rate plummets in 30-year comparison 2
... and American Board of Internal Medicine (ABIM) announce the ... performance evaluation tools for blood specialists. , ... ABIM certification, ASH and ABIM have co-developed the Hematology ... to complete their practice performance assessment requirement for recertification. ...
... research project which could revolutionise the diagnosis and treatment ... four-year project, the results of which are now being ... means of identifying the two most deadly forms of ... for practitioners. , The implications for improving children's health ...
... to ferns to create a novel energy scavenging device that ... provide a method for powering micro and nano devices with ... works," said Michel Maharbiz, assistant professor of electrical engineering and ... the device. "If you build these things they will move. ...
Cached Biology News:New tool helps blood specialists improve patient care 2Hope for major advance in fighting world killer disease 2Hope for major advance in fighting world killer disease 3Ferns provide model for tiny motors powered by evaporation 2
...
Tissue-Stat ( Tissue Adherent for Mounting Formalin-Fixed and Frozen Tissue Sections.)...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
Biology Products: